Answer
VITRAKVI (larotrectinib sulfate) monotherapy treats adults and children with NTRK gene fusion-positive solid tumours that are locally advanced, metastatic, or likely to cause severe morbidity if surgically removed, and who have no satisfactory treatment options.
Sources for this answer
- Vitrakvi 25 mg hard capsulesBayer plc · emc · SmPC §4.1 Therapeutic Indications · Version 14Document updated
Sources checked